Novo Nordisk A/S Class B revenue breakdown overview

Novo Nordisk A/S Class B revenue for the last year amounted to 290.40 B DKK, the most of which — 271.76 B DKK — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 215.10 B DKK. The greatest contribution to the revenue figure was made by United States — last year it brought Novo Nordisk A/S Class B 167.40 B DKK, and the year before that — 127.53 B DKK.